30 results on '"Bachier, C"'
Search Results
2. OUTREACH: PRELIMINARY SAFETY & EFFICACY RESULTS FROM A PHASE 2 STUDY OF LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN THE NONUNIVERSITY SETTING
3. 890MO Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR.T cell, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCL
4. Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial
5. 529 Targeting SIRT1 Activity: a Novel Strategy for Acute Myeloid Leukemia Therapy
6. Oral Loading of Tacrolimus and Sub-Therapeutic Levels on the Day of Transplant Do Not Predict the Incidence of Acute Graft Versus Host Disease or Survival After Allogeneic Stem Cell Transplant
7. Upfront Tandem Autologous Stem Cell Transplant Is Superior Than Autologous or Allogeneic Stem Cell Transplant After Failure of 1st Autologous Transplant in Patients with Multiple Myeloma
8. More Accurate Determination of Blood Volume Allows for a High Correlation of Pre-Apheresis Peripheral Blood and Final Apheresis Product CD34+ Cell Counts
9. Prophylaxis of Acute GVHD Using Multistem® Stromal Cell Therapy: Preliminary Results After Administration of Single or Multiple Doses in a Phase 1 Trial
10. Ethnicity Between Donor and Recipient Affects Overall Survival in Umbilical Cord Blood Transplantation
11. Stromal Stem Cell Therapy for Prophylaxis of Acute GVHD: Preliminary Results From a Phase 1 Trial
12. Multiple Myeloma Patients Over Age 70 Have Similar Clinical and Cost Outcomes for Autologous Transplant Compared to Younger Patients
13. Hematopoietic Stem Cell Apheresis Products With High Mid-Collection WBC Counts Are An Accurate Indicator Of The Final Product WBC Count And Are Associated With Transplant Related Adverse Events
14. Clinical And Cost Outcomes Of Double Umbilical Cord Blood Versus Bone Marrow And Peripheral Blood Unrelated Donor Hematopoietic Stem Cell Transplants
15. Cost Analysis of Mobilization and Autolgous Transplantation in Patients Who Received AMD3100 after Failing Standard Mobilization
16. 300: Once Daily Busulfan Cyclophosphamide is Well Tolerated and Effective Prior to Allogeneic Hematopoietic Stem Cell Transplantation
17. 326: Once Daily Busulfan and Fludarabine is well Tolerated and Effective in Older Heavily Treated Patients Prior to Unrelated Donor Allogeneic Peripheral Blood Stem Cell Transplant
18. 216: AMD 3100 successfully mobilizes autologous CD34+ cells after failure of G-CSF mobilization regimens with low toxicity and acceptable autologous stem cell transplant (ASCT) outcomes
19. Valganciclovir for the prophylaxis of early cytomegalovirus (CMV) infection after allogeneic stem cell transplantation
20. Intravenous busulfan dosed four times daily or once daily as part of the standard BuCy preparative regimen for allogeneic stem cell transplantation
21. Efficacy of fluconazole prophylaxis for autologous peripheral blood stem cell transplantation: Results of a prospective, randomized, controlled, multicenter, open label study
22. Phase II study of a moderate-intensity preparative regimen with allogeneic peripheral blood stem cell transplantation for hematologic diseases: The Texas Transplant Consortium experience
23. A phase II trial evaluating the safety and effectiveness of the AastromReplicell system for augmentation of low-dose blood stem cell transplantation
24. Ig heavy chain CDR3 size diversities are similar after conventional peripheral blood and ex vivo expanded hematopoietic cell transplants
25. Graft failure in a patient with systemic lupus erythematosus (SLE) treated with high-dose immunosuppression and autologous stem cell rescue
26. Infusional Vinorelbine in Relapsed or Refractory Lymphomas
27. Ninety-Six-Hour Paclitaxel Infusion with Mitoxantrone and Ifosfamide/Mesna and Consolidation with ESHAP for Refractory and Relapsed Non-Hodgkin's Lymphoma
28. Use of the International Prognostic Index and the Tumor Score to Detect Poor-Risk Patients with Primary Mediastinal Large B-Cell Lymphoma: A Study of 37 Previously Untreated Patients
29. Paclitaxel (Taxol®) for the treatment of lymphoma
30. Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.